10-K/A: Creative Medical Technology Holdings Files Amended 10-K, Details Executive Compensation and Related Party Transactions

Creative Medical Technology Holdings files an amendment to its 2024 annual report, providing updates on executive compensation, director information, related party transactions, and other corporate governance matters.

Summary

• Creative Medical Technology Holdings filed an amendment to its Form 10-K for the fiscal year ended December 31, 2024.
• The document details information about the company's directors and executive officers, including their backgrounds and committee memberships.
• Executive compensation for Timothy Warbington (CEO) and Donald Dickerson (CFO) is outlined, including salary, option awards, and other compensation.
• The report also covers compensation for non-employee directors, with annual retainers of $80,000 and additional compensation for committee chairs.
• Information on security ownership by beneficial owners, management, and directors is provided as of April 15, 2025.
• Related party transactions, including the StemSpine patent purchase and research and development purchase from related entities, are disclosed.
• The company's Related-Person Transactions Policy and director independence are also discussed.
• Principal accountant fees and services provided by Haynie & Company are detailed for the years ended December 31, 2024 and 2023.
• The document includes certifications from the CEO and CFO regarding the accuracy of the report.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The related party transactions and ongoing obligations could be viewed as slightly negative, while the company's focus on innovation and intellectual property protection is a positive.

Positives

• The company has an audit committee comprised of independent directors meeting SEC and Nasdaq requirements.
• The Board has adopted a Code of Business Conduct and Ethics applicable to directors, officers, and employees.
• The company has a written Related-Person Transactions Policy to ensure fair dealings.
• A third-party analysis of the research tools acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company's research and development expenses over the long term.

Negatives

• The company has engaged in related party transactions, including a $5,000,000 research and development purchase from an entity affiliated with a former director and current consultant.
• The company has ongoing obligations to CMH related to the StemSpine patent purchase, including royalty payments.

Risks

• Related party transactions could raise concerns about potential conflicts of interest.
• The company's reliance on key personnel, such as the CEO and CFO, could pose a risk if they were to leave.
• The biotechnology industry is subject to regulatory risks and the success of clinical trials is uncertain.

Management Comments

• The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products.
• The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development.

Industry Context

The biotechnology industry is characterized by high risk and high reward, with companies often relying on patents and intellectual property to protect their innovations. Creative Medical Technology Holdings' focus on stem cell therapies and related technologies places it in a competitive landscape with other companies developing regenerative medicine solutions.

Comparison to Industry Standards

• Executive compensation at Creative Medical Technology Holdings appears to be relatively modest compared to larger, more established biotechnology companies.
• Director compensation is in line with smaller companies, with a mix of cash and potential stock awards.
• Related party transactions are not uncommon in smaller companies, but they require careful scrutiny to ensure fairness and transparency.
• The company's reliance on Haynie & Company for auditing services is typical for smaller public companies.

Related Party Transactions

• The company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017.
• On December 15, 2022, the company purchased a set of components referred to as research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of ours is affiliated with.

Stakeholder Impact

• Shareholders should be aware of the related party transactions and their potential impact on the company's financials.
• Employees may be affected by the company's strategic decisions and financial performance.
• Customers and partners may be impacted by the company's ability to develop and commercialize its technologies.
• Creditors should monitor the company's financial health and ability to meet its obligations.

Key Dates

Keywords

executive compensation, related party transactions, directors, corporate governance, financial statements, audit committee, Form 10-K, Creative Medical Technology Holdings, biotechnology